コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e requiring angioplasty of a progressive FMD stenotic lesion.
2 n of the total myocardium in jeopardy from a stenotic lesion.
3 IL-2 and IL-15, which are amply expressed in stenotic lesions.
4 une responses appear to predominate in human stenotic lesions.
5 lecules were correlated with the severity of stenotic lesions.
6 significantly higher in nonstenotic than in stenotic lesions (1.3 +/- 0.2 vs. 1.0 +/- 0.2, p < 0.001
7 icantly different between nonstenotic versus stenotic lesions (20 +/- 8 mm(2), n = 23 vs. 22 +/- 8 mm
12 ion, perineural invasion, and lymphangitis), stenotic lesion, emergency surgery, and palliative surge
13 to standard angioplasty for the treatment of stenotic lesions in dysfunctional hemodialysis arteriove
15 tion (PCI) should be considered for severely stenotic lesions in proximal coronaries that subtend a l
17 (OR, 1.32; 95% CI, 1.15-1.53; P < .001), and stenotic lesions (OR, 1.15; 95% CI, 1.01-1.31; P = .03).
18 resorbable scaffold implantation in a simple stenotic lesion resulted in stable lumen dimensions and
19 ss risk in patients with type 2 diabetes for stenotic lesions showed hazard ratios for aortic stenosi
20 flow obstruction and encompasses a series of stenotic lesions starting from the left ventricular outf
21 om a stroke), probably culprit (not the most stenotic lesion upstream from a stroke), or nonculprit (
22 assified as either culprit (the only or most stenotic lesion upstream from a stroke), probably culpri
23 ow often early arterial wall changes lead to stenotic lesions, use of these modalities in combination
26 type 1 and 2 diabetes have greater risk for stenotic lesions, whereas risk for valvular regurgitatio
27 n of the first balloon-expandable valves for stenotic lesions with implantation in the pulmonic posit